.INVESTIGATION HIGHLIGHT.16 October 2024.
In the NIAGARA trial, the enhancement of perioperative durvalumab to standard therapy for muscle-invasive bladder cancer improved event-free as well as overall survival, denoting a new therapy option for this problem.